Paul Hartmann Ag

Alterity Therapeutics' ATH-434 Shows Promise in Slowing Multiple System Atrophy

5 months ago

• Alterity Therapeutics' ATH-434 demonstrated statistically significant slowing of clinical progression in early-stage multiple system atrophy (MSA) patients. • The Phase II trial showed up to 48% of patients experienced a slowing of the disease with the 50mg dose at week 52, as measured by the UMSARS scale. • ATH-434 targets excess iron in the brain, aiming to prevent neuron clumping and restore communication, with biomarker results suggesting reduced iron accumulation and brain volume preservation. • Alterity plans to engage with the FDA for fast-track approval, addressing the significant unmet need for MSA treatment.